This Persistence Market Research (PMR) report examines the global microbiome therapeutics market for the period 2018–2025.The primary objective of the report is to offer insights into market opportunity for microbiome therapeutics and pipeline developments in microbiome therapeutics market.
The microbiome industry is at an early stage but is undergoing rapid developments in last five years. Particular microbiome therapeutics based on human intestinal microbiome are popular and numerous programs are being carried out to evaluate their therapeutic efficacy in treating or preventing gastrointestinal disorders such as C. difficile infection, ulcerative colitis, inflammatory bowel disease (IBD) etc. among others. The market for microbiome therapeutics is primarily driven by government initiatives in funding microbiome research, success of human microbiome project, need for reliable therapeutics for certain disease indications and huge pipeline of novel microbiome therapeutics.
A highly organized report for gaining maximum clarity The report analyzes the global opportunity for microbiome based therapeutics in terms of value (US$ Mn) and forecast.The report begins with the market definition and explaining different disease indications for which microbiome therapeutics are being developed.
The market view point section includes analysis of Persistence Market Research on key trends, drivers, restraints, and macro factors influencing global market. Opportunity analysis and recommendations section provided in the report allows to better equip clients with crystal clear decision making insights.
Section on venture capital provides the analysis of financing activities by venture partners in microbiome therapeutics in last 6-7 years.The section gives detailed description of venture financing along with the capital raised by various players in microbiome therapeutics market from 2011-2017.
The section helps readers to gain insights into the source of financing for novel microbiome therapeutics, most of which are being developed by early stage of clinical stage biotechnology companies.
The next section of the report covers pipeline analysis of microbiome therapeutics.Pipeline analysis section provides analysis by development stage, disease indication, number of active clinical programs by therapeutic area, geographical distribution of clinical trials and analysis by product type.
The section helps readers to identify potential competitors that are working on microbiome based drugs for the same therapeutic area. The section gives detailed description of over 120 clinical, preclinical and discovery programs.
The next section of the report highlights global microbiome therapeutics market potential by various indications including C. difficile infection, preterm birth & gynaecology conditions, type 2 diabetes and obesity. The section provides analysis on the bases of epidemiology and potential patient population for each of the indication mentioned and potential for microbiome therapeutics in the global market compared to currently available treatment drugs/products for each of the indication. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global microbiome therapeutics market.
Competitive landscape section is devoted to studying the competition in this novel market In next section of the report on microbiome therapeutics market, a detailed competitive landscape is included to provide report audiences with a dashboard view, to access the key differentiators among the competitor firms. Detailed company profiles include company-specific long-term and short-term strategies, pipeline products in microbiome therapeutics, recent developments, company’s microbiome activity analysis (in terms of pipeline, disease areas, industry sectors, number of licensing activities, partnerships, acquisitions and venture capital raised since 2010).
By Indication Type 2 Diabetes Obesity difficile infection Primary Hyperoxyurea
By Region U.S. Europe Japan RoW
Our reports have been used by over 10K customers, including:
Cancer is a class of disease which is classified by an uncontrolled cell growth. There are various types of cancer which are affecting millions of individuals all across the world. According to GLOBOCAN, approximately 15.2 Million incidences of cancer were registered in 2015. This number is forecasted to reach an approximate...
Immuno-oncology is a unique approach that uses the body’s immune system to fight cancer. These therapies activate an individual’s immune system, making it able to recognize cancer cells and destroy them. Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment...
Bi-specific antibody is one of the most potentially powerful tools which have emerged in the biopharmaceutical industry. The bi-specific antibodies intend to provide the next generation of targeted biologics by engaging two different targets simultaneously. These drugs offer several advantages over traditional treatment...
The report presents a detailed analysis of the Aeromonads diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Aeromonads definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments:
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Human Parainfluenza Virus 3 (HPIV-3) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Human Parainfluenza Virus 3 (HPIV-3) Infection pipeline products. DISEASE OVERVIEW Human...
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Yellow Fever Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Yellow Fever pipeline products. DISEASE OVERVIEW Yellow fever is a mosquito-borne infection that ranges...